4Kscore Using Serum Stored Uncentrifuged
Demonstrating the Stability of the Analytes Measured for 4Kscore: Total PSA (tPSA), Free PSA (fPSA), Intact PSA (iPSA), and Human Kallikrein 2 (hk2) in Clinical Serum Samples Stored Uncentrifuged Before Testing
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Sidney Kimmel Cancer Center at Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men capable of donating five 5 mL tubes of whole blood
- 40 to 80 years old
- No prior diagnosis of prostate cancer; prior negative prostate biopsy included
- Total PSA (tPSA) value measured within last year to be: at 1.5 ng/mL to 4 ng/mL, 4.1 ng/mL to 10 ng/mL and 10 ng/mL and above
Exclusion Criteria:
- In the previous 96 hours (4 days), underwent a digital rectal exam
- Any invasive urologic procedure in the 6 months prior to study participation
- Underwent any procedure to treat symptomatic benign prostatic hyperplasia in the last 6 months
- Radical prostatectomy since tPSA measurement
- Received within the previous 6 months 5-alpha reductase inhibitor (5-ARI) therapy such as Avodart (dutasteride) or Proscar (finasteride)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tPSA changes in 3 days
Time Frame: Day 0, 1, 2 and 3
|
Measure tPSA in serum samples at day 0, 1, 2 and 3
|
Day 0, 1, 2 and 3
|
|
fPSA changes in 3 days
Time Frame: Day 0, 1, 2 and 3
|
Measure fPSA in serum samples at day 0, 1, 2 and 3
|
Day 0, 1, 2 and 3
|
|
iPSA changes in 3 days
Time Frame: Day 0, 1, 2 and 3
|
Measure iPSA in serum samples at day 0, 1, 2 and 3
|
Day 0, 1, 2 and 3
|
|
hK2 changes in 3 days
Time Frame: Day 0, 1, 2 and 3
|
Measure hK2 in serum samples at day 0, 1, 2 and 3
|
Day 0, 1, 2 and 3
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: James Ryan Mark, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20622
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.